Drug Trial Radar · NCT07680946
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Dec 12, 2028
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
Conditions
- Schizophrenia
Interventions
UblituximabDrug
Administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with at Least 20% Reduction From Baseline in PANSS Total ScoreTime frame: At Week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
Little Rock, Arkansas · Recruiting
TG Therapeutics Investigational Trial Site
Richardson, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.